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Cancer-testis antigens (CTAs) represent an expanding class of tumor-associated proteins deﬁned on the basis of their tissue-
restricted expression to testis or ovary germline cells and frequent ectopic expression in tumor tissue. The expression of CTA in
MHC class I-deﬁcient germline cells makes these proteins particularly attractive as immunotherapeutic targets because they serve
asessentiallytumor-speciﬁcantigensforMHCclassI-restrictedCD8+Tcells.Moreover,becauseCTAsareexpressedinmanytypes
of cancer, any therapeutic developed to target these antigens might have eﬃcacy for multiple cancer types. Of particular interest
among CTAs is the synovial sarcoma X chromosome breakpoint (SSX) family of proteins, which includes ten highly homologous
familymembers.ExpressionofSSXproteinsintumortissueshasbeenassociatedwithadvancedstagesofdiseaseandworsepatient
prognosis. Additionally, both humoral and cell-mediated immune responses to SSX proteins have been demonstrated in patients
with tumors of varying histological origin, which indicates that natural immune responses can be spontaneously generated to
these antigens in cancer patients. The current review will describe the history and identiﬁcation of this family of proteins, as well
as what is known of their function, expression in normal and malignant tissues, and immunogenicity.
1.Introduction
The class of proteins known as cancer-testis antigens (CTAs)
are a subgroup of tumor proteins with normal expression
found almost exclusively in testis germline tissues and
aberrant expression in many types of cancer [1]. More
than 110 CTA genes have been identiﬁed to date, with
approximately 30 members encoded by genes located on
the X chromosome, frequently in multigene families [2].
These CTA genes located on the X chromosome, called CT-X
genes, are predicted to comprise ∼10% of the genes encoded
by X chromosomal DNA, and many of these CT-X genes
have homologues in mice that are also located on the X
chromosome and restricted in expression to testis tissues [2–
4]. Typically, the CT-X genes cluster in two chromosomal
regions, at a telomeric region between Xq24 to Xq28 and a
centromeric region from Xp11.2 to 11.4.
In addition to their tissue-restricted expression patterns,
CTA proteins share a number of other common characteris-
tics. For instance, many are encoded by multigene families,
can be epigenetically regulated in expression level with drugs
such as 5-aza-2 -deoxycytidine, and many have unknown
functionality yet appear to play some role in tumorigenesis.
Additionally, most CTAs have heterogeneous expression in
cancer tissues and are frequently expressed in high-grade
or late tumor stages, with expression often correlated with
a worse prognosis. Tumors expressing one CTA are also
often found to express multiple CTAs, and several have
been found to be targets of spontaneous humoral or cell-
mediated immune responses [2]. The majority of CT-X
antigensareexpressedinthetestisatthespermatogoniastage
of spermatogenesis [5] ,w h e r e a so t h e rC T A sa p p e a rt ob e
restricted in expression to haploid cells [3]. Most nonCT-X
genesaresingle-copy geneswithno chromosomalclustering,
and expression patterns often not entirely restricted to
MHC-deﬁcient germ cells or cancer tissue.
While these proteins represent potential therapeutic
targets for cancer based upon their predominant expression
selectively in tumor tissues, they are particularly attractive as
targets for tumor immunotherapy, speciﬁcally due to their2 Clinical and Developmental Immunology
preferential expression in immune-privileged testis tissue.
Severalphysicalandmolecularmechanismscontributetothe
immunoprivileged nature of testis tissue including localized
cytokine-mediated immune suppression, antigen-speciﬁc
immunoregulation, the presence of the blood-testis barrier,
and an absence of MHC class I molecules on testis germ cells
[6, 7] .T h el a c ko fM H Cc l a s sIo nt h es u r f a c eo fg e r m l i n e
cells means these cells are unable to present endogenous
peptides to the host CD8+ T cells, suggesting that testis-
speciﬁc proteins should be recognized as neo-antigens when
expressed ectopically in tumor tissue elsewhere in the body.
Whiletheimmune-privilegednatureoftestistissuewilllikely
result in decreased peripheral immune tolerance to CTAs
expressed in tumors, it should be noted that some central
tolerancetotheseantigensmaybepresentsinceCTAproteins
could be expressed in lymphoid tissues such as medullary
cells of the thymus during T-cell selection [8]. However,
CTAs encoded by the CT-X genes appear to be the most
promising CTAs as therapeutic vaccine targets since their
expression is most highly restricted to only testis and cancer
tissues compared to other nonCT-X CTAs.
To date, only a few CTAs have been shown to elicit both
humoral and cell-mediated immune responses in humans,
including SSX, MAGE-A1, MAGE-A3, and NY-ESO-1 [2].
These proteins are currently the most promising CTA targets
for tumor immunotherapy, and several clinical trials are
underway to evaluate the eﬃcacy of MAGE-A3 and NY-
ESO-1 as tumor targets [9, 10]. Alternatively, many other
proteins have been evaluated as potential targets for tumor
immunotherapy including tissue diﬀerentiation antigens
such as tyrosinase, Melan A/Mart-1, gp 100, and prostatic
acid phosphatase (PAP) or antigens expressed at low levels
in normal tissues and high levels in tumor tissue such as
HER2 and Muc 1, [11–13]. These proteins may represent
attractive targets for certain speciﬁc types of cancer, however,
the SSX proteins are targets potentially applicable to many
types of cancer instead of tumors of a restricted histological
type.Additionally,theneedtoovercomepreexistingimmune
tolerance to non CTA may represent a larger immunother-
apeutic obstacle for antigens not expressed in immune-
privileged tissue. While SSX proteins appear to be very
promisingtargetsfortumortherapy,theworkevaluatingthis
family as targets for cancer is less advanced compared to the
MAGE or NY-ESO-1 proteins.
This paper will focus on the SSX family of cancer testis
antigens. Recently these proteins have been identiﬁed as
high priority targets for cancer therapy based upon certain
predeﬁned criteria such as antigen speciﬁcity, oncogenicity,
expression level, and number of identiﬁed epitopes [14].
Some members of this family can become fused to the
SS18 protein in synovial sarcoma (SS) through gene translo-
cations, which is how these proteins were ﬁrst identiﬁed.
Interestingly, the SS18-SSX fusion genes are expressed in
>95% of SS and appear to directly contribute to the cancer
phenotype [15]. Much work has been conducted in the
last decade to characterize this family of proteins, and
although a great deal of information has been elucidated
regarding their expression patterns, functionality, cellular
localization, and immunogenicity, their role in cancer is still
incompletely understood. The information obtained from
these investigations has only emphasized the importance of
SSX proteins as tumor targets.
2. SSX Identiﬁcation
The SSX gene family was ﬁrst identiﬁed through cytogenetic
studies of synovial sarcoma (SS) in which approximately
70% of both biphasic and monophasic SS tumor types
were found to contain the same characteristic chromoso-
mal translocation event t(X;18)(p11.2;q11.2) [16–19]. By
screening a cDNA library derived from a SS cell line with
a yeast artiﬁcial chromosome (YAC) probe spanning the
t(X;18) chromosome breakpoint, Clark et al. identiﬁed two
novel genomic fragments by Southern blot analysis. Both of
these transcripts, when sequenced, failed to exhibit strong
homology to any published genomic sequences and were
thus designated SYT for “Synovial Sarcoma Translocation”
(now known as SS18 for Synovial Sarcoma gene of chromo-
some 18) and SSX for “Synovial Sarcoma X chromosome
breakpoint” [20]. It was further found that the C-terminus
of SSX was fused with the N-terminus of SS18, which
indicated that the translocation would result in an SS18-
SSX fusion protein. Because of the presence of this fusion
event in such a high percentage of SS, it was predicted that
this fusion protein must have inherent transforming activity
independent of the normal function of the SS18 and SSX
proteins.
Sequencing additional SS cDNA clones of this fusion
site, Crew et al. found that the C-terminal regions of two
distinct genes, designated SSX1 and SSX2, can become
fused to the N-terminus of SS18 [21]. In the case of
both genes, it was observed that the last 78 C-terminal
amino acids of SSX1 and SSX2 replaced the last 8 amino
acids of the C-terminus of SS18 in most tumors, how-
ever, alternate fusions were also observed less frequently
for some tumor specimens. Based upon their predicted
open-reading frames, these two genes were expected to
encode proteins of 188 amino acids, exhibit ∼81% protein
sequence identity, contain consensus sequences for both
N-glycosylation and tyrosine phosphorylation, be rich in
charged amino acids (40%-41%), and in particular both
proteins were found to have acidic C-terminal tails that are
sometimeshallmarksofnuclearproteins.Usinganonspeciﬁc
SSX probe, they also found by Northern blot that SSX1
and SSX2 expression was restricted to thyroid and testis
tissues.
T¨ ureci et al. later identiﬁed SSX2 as the cancer testis
antigen (CTA) HOM-Mel-40 when it was found that some
melanoma patients have IgG antibody immune responses
speciﬁc for SSX2 using the serological analysis of recombi-
nant cDNA expression libraries (SEREX) methodology [22].
By screening a cDNA library derived from melanoma tissue
with sera from multiple melanoma patients it was found
that high-titer IgG antibodies to HOM-Mel-40/SSX2 were
found in approximately 10% of patients with melanoma
(10/89), whereas SSX2 responses were absent in sera from
healthy controls (0/41). In the same report, it was foundClinical and Developmental Immunology 3
that out of 32 tissues evaluated for SSX2 expression by RT-
PCR and Northern Blot, SSX2 expression was restricted
to testis tissue, and contrary to the report by Crew et
al. expression in the thyroid was barely detectable by RT-
PCR, whereas SSX2 expression was found in the testis by
both Northern blot and RT-PCR. These results conﬁrmed
that SSX2 is essentially testis-speciﬁc among normal body
tissues. T¨ ureci also reported in the same paper that SSX2 was
expressed in about 50% of melanoma tumor samples, 30%
of hepatocellular carcinoma tumor samples, 25% of colon
and prostate cancer samples, 20% of breast cancers, and
several other tumor samples of diﬀerent histological origin
examined by RT-PCR. These ﬁndings ﬁrmly established
the inclusion of SSX2 as a member of the CTA class of
proteins. The presence of SSX2 expression in so many tumor
types suggested that this antigen is upregulated in cancer
independently from fusion events with SS18, perhaps by
alterations in methylation status or by the overexpression of
SSX2 transcriptional activators. In fact, it has been shown
cytogenetically by several groups that the fusion member
derived from the X chromosome (“der(X)” or SSX2) rather
thanthederivativememberfromchromosome18(“der(18)”
or SS18) is important for maintaining proliferation and
that der18 can be lost during the course of SS progression
suggesting that the expression of the C-terminal portion
of SSX may be the dominant event leading to tumor
progression [16, 17, 19, 23, 24].
3.A FamilyofProteins
A short time after the identiﬁcation of the two SSX proteins
involved in the SSX-SS18 fusion event it became clear that
SSX1 and SSX2 were part of a larger family of homologous
proteins, numbered sequentially based on their discovery. A
study by Chand et al. using a pulse-ﬁeld analysis of digested
YACs spanning the X chromosome (OATL1 loci), revealed
that perhaps as many as ﬁve copies of the SSX gene were
present in this region. The analysis indicated that SSX or
this genetic locus had undergone a series of duplication
events [25]. Following on these observations, de Leeuw and
colleagues identiﬁed a third SSX family member designated
SSX3 by screening a testis cDNA library [26]. This gene
had 90% identity to SSX1 and 95% identity to SSX2 at the
nucleic acid level. Additionally, somatic cell mapping studies
indicated that this third family member was located in the
same region of the X chromosome (Xp11.2 → p11.1) as
SSX1/2. However, in contrast to SSX1/2, RT-PCR data from
44 SS tumor samples revealed that SSX3 was not a fusion
partner with SS18.
SSX family members SSX4 and SSX5 were subsequently
identiﬁed by Southern blot analysis using PCR and restric-
tion map analysis [27]. Human genomic DNA was probed
using a 32P-labeled SSX cDNA and the genomic DNA pulled
out was sequenced for identiﬁcation. The two new members
brought the total membership of the SSX protein family
to ﬁve, including a shorter SSX4 transcript representing an
alternative splice. These family members shared 88–95%
nucleotide homology and 77–91% amino acid homology.
Cloning and sequencing of SSX2 as a prototypic SSX gene
revealed a coding region containing six exons spanning a
total genomic distance of 8kb. RT-PCR showed that all ﬁve
members were expressed in the testis. Further PCR analysis
ofmelanomacelllinesindicatedcommonexpressionofSSX1
and SSX2 (3/12 lines), while SSX4 and SSX5 detection was
more rare (1/12), and SSX3 expression was not detected [27].
Not long after the ﬁrst ﬁve homologues were described, a
sixth family member, SSX6, was identiﬁed through database
searchesbydosSantosetal.[28],andthreeadditionalunique
memberswereidentiﬁedbyG¨ ureetal.throughthescreening
and sequencing of a placenta genomic library with an SSX
probe and extensive database analysis [29]. This brought the
SSX gene family to a total of 9 members. In these database
queries, ten additional SSX pseudogenes were identiﬁed, all
of which mapped to chromosome X with the exception of
ψSSX10 found on chromosome 6. The protein homology of
these family members ranges from 73%–92%, and the cDNA
homology was found to be between 87%–96%.
Each SSX homologue was found to encode the KRAB-
A domain on two exons (4 and 5) and the SSX repres-
sion domain (encoded by exon 9), described below, and
each complete gene occupied 8–10kb with the distance
betweengenesontheXchromosomerangingfrom10–50kb.
However, in contrast to their previous study, which found
that SSX members have 6 coding exons, further analysis
of expressed sequence tags (ESTs) in GenBank revealed
additional 5  and 3  exons in untranslated regions. This
ﬁnding brought the total number of SSX exons to 10;
however, it was found that only 8 of the 10 exons are
utilized by all SSX members. From these sequencing studies,
the authors conﬁrmed that all members share conserved
exon/intron junctions, exon sizes, and most introns, with
a few exceptions for alternative splice isoforms (i.e., SSX2,
SSX4, SSX5 and SSX7). SSX1–9 were all predicted to encode
proteins of 188 amino acids except for SSX8 which has a
premature termination in the 7th exon and is predicted
to encode a shorter protein of 142 amino acids. Protein
expressionofSSX8aswellasthealternativesplicevariantsfor
SSX2, 4, 5, and 7 have not been shown. With the exception of
ψSSX10 on chromosome 6, all SSX genes and pseudogenes
were found to cluster within two loci on the X chromosome
2mb apart. Based on the observed clustering of SSX family
members within the contigs available in GenBank, G¨ ure and
colleagues suggested that the two main SSX gene clusters
arose from a large duplication spanning an approximately
100kb region [29]. A tenth SSX family member, designated
SSX10 and predicted to encode a protein product, has been
annotated in GenBank (GeneID: 100128582), but to date
no information about its expression in normal or malignant
tissues has been described.
The discovery that the SSX family contains several pro-
tein members is very characteristic of other CT-X antigens
described thus far. For instance, it has been shown that the
MAGE-Afamilyconsistsof12members,GAGE16members,
NY-ESO3members,andtheSPANXfamilyhas12members,
just to name a few of the more than 110 CTAs identiﬁed to
date [2]. Not only have many SSX homologues been deﬁned
in humans, but several orthologues have been annotated for4 Clinical and Developmental Immunology
other species as well. The known SSX orthologues appear
to be restricted to mammalian genomes with several SSX
orthologues ﬁled in the NCBI GenBank database includ-
ing Homo sapian (human; accession XP 001128182), Pan
troglodytes (chimpanzee; accession XP 001137291), Macaca
mulatta (Macaque; accession XP 001103483), Callithrix jac-
chus (Marmoset; accession XP 002762880), Canis lupus
familiaris (domesticated dog; accession XP 855346), Equus
caballus (horse; accession XP 001917891), Rattus norvegicus
(Norway rat; accession XP 002727549), and Mus musculus
(common house mouse; accession EDL33981.1). All of these
orthologues share the SSX repression domain (SSXRD),
described below, and KRAB domains that are common
amonghumanSSX(hSSX)familymembers,withtheSSXRD
being the most highly conserved (Figure 1).
Several of the identiﬁed SSX orthologues, like human
SSX (hSSX), appear to have homologous members within
a species. For instance, a family of as many as 13 murine
homologues have been well characterized on the mouse
X chromosome [30]. These genes were ﬁrst identiﬁed by
Chen et al. by sequencing cDNA clones from mouse testis
and tumor tissues. The mouse homologues were divided
into two distinct classes, “Ssxa” and “Ssxb,” based on
their sequence homologies. Ssxa consists of one member
(Ssxa1), while Ssxb was found to have 12 members (Ssxb1–
12). Ssxb family members were highly homologous overall
with 75–98% nucleotide homology and 67–99% protein
homology, however Ssxa and Ssxb were only approximately
30% homologous to each other, showing relatively large
diversity between these two classes. These orthologues were
locatedonchromosomeX:cMposition5.9,andinterestingly,
this region is syntenic with human chromosome Xp11.3–
p11.23 where the hSSX family members cluster. Again, like
hSSX,theconservedSSXRDandKRABdomainsareencoded
byoneandtwoexons,respectively.Allintronsizesaresimilar
between human and mice SSX genes, and all SSX genes span
genomic regions of 8kb. Also, like hSSX family members,
some mouse (mSSX) homologues were expressed in murine
tumors (predominantly Ssxb1 and Ssxb2), whereas others
were not, and Ssxa and Ssxb mRNA expression was restricted
to testis tissue among other normal tissues. Overall, mSSX
genes are less than 35% homologous to hSSX, however, the
KRAB and SSXRD domains were found to be as much as 49–
66% homologous depending on the hSSX/mSSX members
being compared [30]. The distinct similarities in expression
patterns and other characteristics shared between mSSX and
hSSX suggest that these orthologues may serve as useful
models systems for preclinical tumor therapy studies.
4. SSX Function
4.1. Domain Functions and Cellular Localization. Like most
CTAs, the function of SSX proteins, as well as the fusion
partner SS18, is still not fully understood. It was determined
from the initial identiﬁcation of SSX that these proteins
have KRAB-like domains and consensual sequences for N-
glycosylation and tyrosine phosphorylation [21, 26]. Since
SSX proteins also have an acidic tail [21]a n daK R A B
domain shown to have transcriptional repressor activity in
a subgroup of zinc ﬁnger proteins, it was surmised that
SSX may be involved in transcriptional regulation [31, 32].
Some of the ﬁrst work characterizing the function of SSX
proteins was carried out by dos Santos et al. evaluating
the subcellular localization of FLAG- or VSV-tagged SS18,
SSX, and the SS18-SSX2 fusion constructs using speciﬁcally-
designed polyclonal antibodies [33]. They found that all
three proteins were expressed in the nucleus of COS-1
cells transfected with constructs encoding cDNAs for these
proteins. SSX2 had a diﬀuse pattern of expression in the
nucleus, while SS18 and SS18-SSX2 had more punctate
nuclear expression patterns [33], with no expression found
in nucleoli. Staining of SS cells or HeLa cells with these
antibodies revealed a punctate pattern of expression similar
to that found for SS18- and SS18-SSX-transfected COS-
1 cells. Double labeling of SS18 or SS18-SSX proteins
with other known nuclear domains in COS-1 cells revealed
no signiﬁcant colocalizations or associations. These results
suggested that SS18 may be directing SS18-SSX fusion
proteins to SS18-associated regions in the nucleus where the
fusion protein may exert abnormal eﬀects. This was later
found to be incorrect, with the SSX domain directing the
fusionconstructstosubcellularlocations,asdescribedbelow.
In addition to these ﬁndings, dos Santos and colleagues also
identiﬁed three putative bipartite nuclear localization signals
(NLSs) that had not been previously reported. These NLSs,
rich in lysine and arginine residues, were distributed along
the protein sequence (aa9–23, aa52–64, aa158–172) with
NLS3 (aa158–172) completely conserved among the known
SSX family members. Following on this work, it was found
shortly thereafter that the SS18 domain of SS18-SSX fusion
constructs can act as a transcriptional coactivator (70-fold
activation) and SSX1 could act as a transcriptional repressor
(50-fold repression) when these constructs were coupled to
a GAL4 DNA-binding domain in reporter assays [34]. These
investigators theorized that the C-terminal SSX domain may
actuallydirecttheSS18activationdomaintonewordiﬀerent
target promoters.
Lim and colleagues later conﬁrmed that the SS18-SSX1/2
proteins are transactivators, while the KRAB domains of SSX
genes function as low-level transcriptional repressors [35].
In GAL4 repression assays the KRAB domains alone from
SSX1 and SSX2 downregulated transactivation of a reporter
gene by 3.5- and 3.3-fold, respectively, compared to >83-
fold repression for a control KOX1-KRAB domain that has
been shown to have potent repression activity [36]. This
result further suggested that the SSX-KRAB domain may
not function the same way as in other KRAB-containing
proteins. Interestingly, the full-length SSX1 protein was able
to repress transactivation in the GAL4 assay by 74-fold.
They therefore postulated that another repression domain
must exist in SSX that is distinct from the KRAB domain.
Assaying deletion constructs, they narrowed down the area
of the protein responsible for this repression to the last 33
C-terminal amino acids of SSX2. They called this domain
the SSX repression domain (SSXRD), which was predicted
to fold into an alpha helix. This domain had greater than
95% homology among the ﬁrst ﬁve SSX family membersClinical and Developmental Immunology 5
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Figure 1: Protein homology and conserved domains among SSX orthologues. Shown is a sequence alignment of species-speciﬁc SSX
protein sequences from canine, horse, human, macaque, chimpanzee, marmoset, mouse, and rat sources. Blue highlighting represents >75%
sequence identity with consensus sequence shown on the bottom. The KRAB and SSXRD domain regions denoted by solid green bars are
shown below the sequence alignment.
identiﬁed at the amino acid sequence level and no homology
was found for this domain among any proteins in the
ProDom database within SwissProt. Of note, this domain
is retained in SS18-SSX fusion proteins and therefore may
contribute to the functional activity of this fusion construct.
Since the full-length SSX protein was found to have greater
repression activity in reporter assays than the SSXRD itself,
this suggested that the KRAB domain may augment the
activity of the SSXRD.
The domains of SS18 and SSX responsible for nuclear
and spatial targeting were later delineated by dos Santos et
al. [37]. Creating a series of FLAG- or VSV-tagged deletion
mutants, they showed that the N-terminal amino acids 51 to
90 of SS18 are responsible for its nuclear localization, even
though this region does not contain an NLS, whereas SSX
nuclear targeting was dependent on the last 34 C-terminal
amino acids (SSXRD). Since this domain is conserved
between family members in humans and other species, it
suggests that this region is used in nuclear targeting for all
SSXproteins.TheputativeNLS3,whichwaspredictedearlier
by dos Santos et al. to be the dominant SSX NLS [33],
was conﬁrmed by amino acid substitutions to play a role in
nuclear targeting. However, knockout of NLS3 resulted in
both cytoplasmic and nuclear staining suggesting that SSX
mayuseadditional,nonbasicaminoacidresiduesfornuclear
targeting.Additionally,itwasobservedfromtruncatedSS18-
SSX constructs that the SSXRD is required for subnuclear
localization for the fusion protein, producing the diﬀuse,
even staining and ﬁne punctate dots observed by others
[33, 34, 38]. Furthermore, these truncation experiments
showed that the SSXRD is responsible for the association of
SSX with mitotic chromosomes and localization to sites of
Polycomb group silencing complex bodies (PcG bodies) in
both transfected cells and 518A melanoma cells, suggesting
that these functions of the SSXRD are endogenous.
Another SSX domain was also identiﬁed by dos Santos et
al. which is immediately upstream of the SSXRD and shows
relatively high divergence in sequence between SSX family
members [37]. They called this sequence the SSX divergent
domain (SSXDD), and its function remains unknown.
4.2. Interaction with the Polycomb Group Silencing Complex.
To further elucidate SSX protein function, Soulez et al. car-
ried out immunolabeling experiments with hemagglutinin
(HA)-tagged SS18, SS18-SSX1, SS18-SSX2, SSX1, and SSX2
proteins expressed exogenously in transfected COS-7 cells,
the SS cell line CME-1, and in the human ﬁbrosarcoma cell
line 2C4 [38]. As observed by dos Santos et al. [33], the
expression patterns of SSX1 and SSX2 were diﬀuse, whereas
SS18 constructs were punctate. However, in the Soulez
paper, toroidal-like structures were observed in 2C4 cells
transfected with SS18 or SS18-SSX1/2, and two prominent
foci were observed in the cells transfected with SS18-SSX1/2
or SSX1/2. To determine if these proteins colocalize with any
known nuclear compartments, these investigators carried
out double immunoﬂuorescence studies with antibodies
against SS18, SSX, and other characterized nuclear antigens.
Soulez and colleagues conﬁrmed that neither SSX, SS18,
nor the fusion constructs localize at sites of active tran-
scription, however, they did ﬁnd that SS18-SSX1 and SS18-
SSX2 expression colocalized with members of the polycomb
group (PcG) complex [39]. Speciﬁcally, SS18-SSX2 was
f o u n dt ol o c a l i z et os i t e so fR I N G 1e x p r e s s i o ni na l lc e l l s
examined, and SS18-SSX1 and SS18-SSX2 colocalized to
sites of endogenous BMI-1 expression (both members of
the PcG complex). Further labeling experiments showed
no association between SS18 and BMI-1, yet SSX1 and
SSX2 were both shown to colocalize with BMI-1. This
result suggested that the SSX portion of SS18-SSX directs
localization of the fusion constructs within the nucleus
to sites of PcG body accumulation, contrary to what was
previously theorized by dos Santos et al. and Brett et al.
[33, 34]. Speciﬁcally, it has been shown that the SSXRD is
responsibleforassociationofSSXwithPcGproteinsandcore
histones [37, 40].
Although much is still not known about the function of
PcG complexes in mammals, it has been demonstrated that
these protein complexes have some role in the regulation of
cell cycle progression and diﬀerentiation [41]. PcG knockout
experimentsandoverexpressionstudieshaveshownthatPcG
genes are associated with proliferation of progenitor cells in
the murine haematopoietic system, with BMI-1 overexpres-
sion leading to lymphoma development [42, 43]. It has been
shown in Drosophila that multimeric PcG complexes func-
tion to maintain homeotic gene silencing, serving as a stable
repressor system to ensure the proper timing of developmen-
tal programs [44, 45]. Like SSX proteins, many PcG complex
members lack DNA-binding domains and are believed to
exerttheirrepressivefunctionsthroughepigeneticregulation
of chromatin structure via protein-protein interactions [46].
Coimmunoprecipitation studies of tagged SSX or SS18-SSX
using antibodies for RING-1 and BMI-1, however, showed
no direct association between these proteins. This result
suggested that SSX may interact with other components of
the large PcG complexes, perhaps proteins not yet identiﬁed
(Figure 2). Since it had been previously reported that PcG
complexes interact with chromatin throughout mitosis [39],
Soulez et al. carried out immunolabeling experiments of6 Clinical and Developmental Immunology
transfected cells with propidium iodide-stained chromatin
to determine if SSX associates with condensed chromatin
[38]. No association was found between SS18 and chromatin
distribution, however both SSX1 and SSX2 were found to
be distributed evenly over condensed chromosomes during
mitosis with especially dense staining during prometaphase
and metaphase. Unlike SSX1 or SSX2, SS18-SSX2 associated
with prometaphase/metaphase chromosomes in punctate
patterns similar to those described for RING-1 and BMI-1
[39],perhapssuggestingafunctionaldiﬀerencebetweenwild
typeSSXandthefusionprotein thatcouldpotentiallyleadto
SS.
4.3. Interaction with RAB3IP and SSX2IP. Using yeast two-
hybrid assays and glutathione-S-transferase (GST) pull-
down assays, de Bruijn et al. identiﬁed the ﬁrst two proteins
that directly associated with SSX2 [47]. Three clones were
identiﬁed from the yeast two-hybrid screens, encoding
sequences 1.1, 1.5, and 1.7kb long. The 1.7- and 1.5-kb
clones pulled out were sequenced and identiﬁed as RAB3IP,
a human homologue of the Rattus norvegicus Rabin3 gene,
which shared 84% cDNA and 88% protein identity, respec-
tively. The two diﬀerent-sized clones were found to be
alternative splices of RAB3IP,a n dw e r ed e s i g n a t e dRAB3IPα
and RAB3IPγ,w i t hRAB3IPα encoding a predicted 51kDa
protein 460 amino acids long, which is analogous to Rabin3
in rats. The 1.7- and 1.5-kb inserts also showed homology
to the Pat-12 gene that has been characterized in mice [48].
Both Rabin3 and Pat-12 genes are thought to potentially
encode Ras-like GTPase-binding proteins, but these proteins
are not fully characterized [49]. The 1.1-kb clones identiﬁed
as SSX2IP were predicted to encode a 71kDa protein 614
amino acids long, which had no homology to any known
sequences. RAB3IP did not interact with SSX1, SSX3, or
SSX4, whereas SSX2IP interacted with SSX3 but not SSX1
or SSX4, which may suggest that the SSX members have
diﬀerent functions. By carrying out deletion mutant studies,
they also determined that these two proteins interact with
the N-terminal moiety of SSX2, with RAB3IP interacting
with SSX2 aa 25 to 80 and SSX2IP interacting with SSX2
a a1t o8 0( Figure 2). Interestingly, the region of SSX2 that
interacts with RAB3IP almost exactly overlaps with the SSX2
KRAB domain, which spans aa 20 to 83. Since RAB3IP
was found to be expressed in many diﬀerent tissues by
Northern blot analysis and has homology to proteins in
speciesasdi v erseasC.elegansandyeast,itwassuggestedthat
RAB3IP may be a house-keeping gene. Murine homologues
to SSX2IP were identiﬁed from blast analysis and ubiquitous
expression was found for this gene as well. The presence
of four coiled-coil domains, and its homology to known
structural proteins, suggests that SSX2IP may function in
nuclear architecture, while the many motifs identiﬁed in
RAB3IP, including coiled-coiled and ER-retention motifs,
indicate that this protein may carry out diverse functions.
Interestingly, RAB3IP is found on chromosome 12q13-14,
a region known to be frequently rearranged or ampliﬁed
in human cancers [50, 51], and SSX2IP is on 1p22 also
in a region commonly deleted, ampliﬁed, or translocated
in human tumors [52–54]. Immunoﬂuorescence studies
showed that RAB3IP normally localized to the cytoplasm
(like Rabin3), but interestingly, when cells were transfected
with both RAB3IP and SSX2, 10% of RAB3IP protein
translocated to the nucleus, whereas SSX2IP was always
shown to colocalize with SSX2 in the nucleus [47].
Further analysis of SSX2IP was recently reported by
Breslin and colleagues in a review on SSX2IP and its
emerging role in cancer [55]. They report that SSX2IP was
identiﬁed as a leukemia antigen through a SEREX screen,
speciﬁcally recognized in the sera of patients with acute
myeloid leukemia (AML) as compared to sera from healthy
donors, and that SSX2IP expression was found in 33%
of leukemic cells from AML patients but not in normal
donor hematopoietic cells tested by RT-PCR [56]. SSX2IP
has also been shown to be highly expressed on the cell
surface of myeloid leukemia cells and AML tissue samples
using immunohistochemistry, ﬂow analysis, and confocal
microscopy [57]. This surface expression on myeloid
leukemia cell lines appeared to peak during mitosis.
SSX2IP is also known as human afadin DIL domain-
interacting protein (ADIP) for its homology to the mouse
and rat ADIP genes, which are 88% and 87% identical
to SSX2IP, respectively. Microarray data has demonstrated
lower expression of SSX2IP in AML patients with t(8;21)
translocation, while higher expression of SSX2IP was asso-
ciated with the t(15;17) translocation [58]. Of note, other
genes elevated in expression in patients with the t(15;17)
translocation include proteins involved in cell cycle reg-
ulation (e.g., p57Kip2, cdk7, cyclins D2, D3, E2 and B2),
replication (Cdc6), and mitosis (survivin and CENPJ). In
human leukemias, SSX2IP appeared to be expressed in cell
cycle-regulated patterns.
4.4. Interaction with LHX4. In an attempt to comprehen-
sively identify proteins that associate with SSX, de Bruijn and
colleagues conducted yeast two-hybrid studies and found
thatoneoftheclonespulledoutencodedtheLIMhomeobox
protein LHX4 [59]. This protein was previously shown to be
deregulated or translocated in multiple forms of leukemia
[60–64]. The C-terminal SSXRD domains of SSX1, SSX2,
and SSX4 all interacted with LHX4 in yeast two-hybrid
assays, suggesting that this protein interaction is common to
SSX proteins. LHX4 is a 390 amino-acid protein containing
two LIM domains (LIM1 and LIM2), a homeobox domain
(HOX), two zinc ﬁngers, and was found to have a C-
terminal tail with a novel transcriptional activation domain.
Utilizing immunoﬂuorescence, de Bruijn and colleagues
demonstrated that SSX1 and SS18-SSX colocalized with
LHX4 in transfected COS1 and HeLa cells; however, in
a small percentage of cells the overlap was not entirely
complete suggesting that these interactions between SSX1
and LHX4 are dynamic. The interaction of SSX1 and
SS18-SSX with LHX4 was subsequently veriﬁed through
coimmunoprecipitation analysis. To evaluate whether SSX
or SS18-SSX can alter the expression of LHX4 target genes,
de Bruijn et al. conducted ChIP and transactivation assays.
The glycoprotein hormone-α (CGA) gene, encoding CGA,Clinical and Developmental Immunology 7
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Figure 2: Functional interactions of the SSX proteins. The RAB3IP and SSX2IP protein interaction with the SSX KRAB domain and LHX4
and PcG protein interactions with the SSXRD domain are depicted. Dynamic intracellular and intranuclear interactions are highlighted.
is a known target of LHX4 binding and transcriptional
regulation [65]. LHX4 was shown to bind directly to the
CGA promoter, with increased CGA transactivation in
conjunction with SS18-SSX2 in luciferase reporter assays of
transfected SYO1 SS cells. Interestingly, in similar assays it
was found that SSX2 alone actually had an inhibitory eﬀect
on CGA activation, which indicates that SS18-SSX2 and
SSX2 have opposite activities of transcriptional regulation
in SS. It was proposed in this study that the interaction
between SSXRD and LHX4 may be dynamic, with LHX4
competing with PcG proteins for the SSXRD, perhaps
altering the transcriptional corepression activities of SSX
(Figure 2).
4.5. Expression in Mesenchymal Stem Cells. The expression
patterns of CTA proteins in testis germline cells that are
constantly undergoing proliferation prompted Cronwright
and colleagues to evaluate SSX expression in normal somatic
cells that are also capable of self-renewal and endless
proliferation [66]. Speciﬁcally, this group investigated the
expression of members of CTA gene families including
NY-ESO-1, MAGE-A, GAGE, RAGE, and SSX in human
postnatal bone marrow and fetal liver mesenchymal stem
cells (MSCs). SSX was found to be expressed in melanoma
cells, fetal MSCs, adult MSCs, and bone marrow by RT-PCR.
Surprisingly, immunoﬂuorescence analysis of MSCs showed
both ﬁne and granulated patterns of SSX expression in the
cytoplasm of these cells. Bone marrow smears stained for
SSX expression showed a few SSX-positive cells that were
also CD34+ (hematopoietic stem cells). Immunostaining
the MSCs for CTAs after the cells were allowed to partially
diﬀerentiate into adipocytes or osteocytes, Cronwright’s
group observed that the CTA expression was markedly
decreased, especially for SSX [66]. This result was con-
ﬁrmed by RT-PCR analysis as well. Decreased levels of
SSX expression were also observed in human fetal tissues
allowed to diﬀerentiate. Double-immunolabeling of SSX
with known proteins associated with migration, invasion,
and metastasis were also carried out. The speciﬁc proteins
evaluated were matrix metalloproteinase 2 (MMP2), which
cleaves a number of cell matrix proteins and is associated
with invasion and metastasis, vimentin, a component of
cytoskeleton intermediate ﬁlaments, and ﬁbronectin and
laminin, involved with cell adhesion. SSX colocalized with
both MMP2 and vimentin. SSX expression was observed
to overlap with laminin but no direct colocalization was
observed, whereas no overlap was observed with ﬁbronectin.
Direct associations between SSX and these proteins were not
observed from coimmunoprecipitation studies, however it
was found that when melanoma cell line DFW (known to
express SSX) was knocked out for SSX expression, DFW cells
had 40% decreased ability to migrate in soft agar compared
to SSX+ DFW cells, and this reduction was accompanied by
a decrease in MMP2 expression. Vimentin and E-cadherin
levels were not inﬂuenced by lack of SSX expression in
these cells. Also, it was observed that SSX expression is
a b l a t e dd u r i n gM S Cd i ﬀerentiation, while MMP2 expression
decreases and vimentin levels remain unchanged. Overall,
even though SSX was not found to directly interact with
MMP2, it does appear to indirectly inﬂuence its expression
patterns, implicating a link between SSX expression and
the processes of self-renewal and tumorigenicity. This study
provided the ﬁrst potential evidence of a link between SSX
expressionandtheprocessesofcellmigrationandmetastasis.
It was also proposed in this study that if CTAs are expressed
in stem cells with limitless proliferation potential then their
ectopic expression in tumor tissue may be a hallmark of8 Clinical and Developmental Immunology
dediﬀerentiation back into a stem-cell like state, perhaps
through an altered regeneration program [66].
5. SSX Expressionin Testis andTumor Tissues
The normal expression of SSX mRNA has been shown by
multiple investigators to be predominantly restricted to testis
germline tissue [21, 22, 27, 67]. SSX protein expression
in the testis is predominantly localized to the nucleus of
spermatogonia cells and occasionally in spermatocytes as
demonstrated by IHC [68]. These expression patterns were
heterogeneous, with only a subset of spermatogonia found
to have SSX nuclear staining. Constitutive genome-wide
demethylation has been demonstrated in spermatogonia
cells where SSX proteins are normally expressed [69, 70],
and interestingly, these same global demethylation patterns
have been observed in tumor tissue and tumor cell lines
and are associated with the reactivation of silenced genes
[71, 72]. This ﬁnding indicates that the same physiological
mechanisms that lead to SSX expression in the testis may
be ectopically reactivated in tumor tissues. Except for SSX6
and SSX10, expression of all SSX family members has been
demonstrated in testis tissue (Table 1)[ 29, 73].
The expression of SSX family members has also been
demonstrated ectopically in many types of cancer (Table 2).
When T¨ ureci et al. initially identiﬁed SSX2 as the tumor
antigen HOM-Mel-40, they also reported by RT-PCR and
Northern blot that SSX2 mRNA was expressed in the
following tumor tissues: melanoma (8/16), colorectal carci-
noma (9/35), prostate cancer (5/25), breast cancer (7/36),
hepatocellular carcinoma (3/6), glioma (2/23), lymphoma
or leukemia (1/9), gastric carcinoma (1/12), and thyroid
carcinomatissuesamples(2/4)(Table 2)[22].In1996T¨ ureci
et al. carried out a more comprehensive study evaluating
SSX family member mRNA expression in cancers of diﬀerent
histological types. In this analysis they found that SSX1,
2, and 4 were expressed in 8%, 15%, and 15% of tumors,
respectively, with no detection of SSX3 in any samples
and detection of SSX5 in only 7 out of the total 325
tumor specimens evaluated [76]. Speciﬁcally, SSX mRNA
was expressed in 75% of synovial sarcoma, 57% of head
and neck cancer, 55% of bladder cancer, 50% of ovarian
cancer,43%ofmalignantmelanoma,40%ofprostatecancer,
36% of nonHodgkin’s lymphoma, 33% of stomach cancer,
27% of colorectal cancer, 21% of breast cancer, 21% of lung,
16% of glioma, 13% of endometrial, and 4% of renal cell
carcinoma tissues (Table 2). Expression of more than one
SSX family member was found in several tumor types, and
altogether 27% of tumor tissues expressed at least one SSX
family member.
InotherreportsofSSXfamilymembertumorexpression,
SSX5 expression has been found in multiple myeloma
[86], osteosarcoma [89], and hepatocellular carcinoma [81],
while SSX1 expression has been found in these tumors as
well as nonsmall cell lung cancer, Hodgkin’s lymphoma,
nonHodgkin’s lymphoma, leukemia, bladder cancer, breast
cancer, colorectal cancer, endometrial cancer, head and neck
cancer, and malignant melanoma [76, 77, 80–84, 86, 88, 89].
SSX2 and SSX4 expression have been found in all of the
cancer types listed above as well as neuroblastoma, gastric
cancer, ovarian cancer, synovial sarcoma, mesothelioma
(SSX2), pancreatic cancer (SSX4), and intrahepatic cholan-
giocarcinoma (SSX4) (Table 2)[ 22, 76–92]. SSX expression
has also been evaluated by RT-PCR in brain tumors in which
SSX1 was only expressed in astrocytomas, while SSX2 was
expressed in astrocytomas and oligoastrocytomas, and SSX4
was expressed in both of these as well as oligodendrogliomas
[92].
Using a novel sequence-based ampliﬁcation assay to
determine SSX mRNA quantities in 211 bone and soft tissue
tumor specimens, Naka et al. found that SSX expression lev-
els varied greatly among tumor samples, and they found that
malignanttumorsshowedmuchhigherSSXexpressionlevels
t h a nb e n i g nt u m o r s( P<. 0001) [93]. Additionally, stage
III tumors had signiﬁcantly higher SSX mRNA expression
levels as compared to stage I or stage II tumors (P<. 005).
These results associated SSX expression with more advanced
stage of disease in cancer patients. In another study by Taylor
et al. it was found that SSX1, SSX2, SSX4, and SSX5 were
all coexpressed in 20% of patients with multiple myeloma
(MM), and this coexpression was found to correlate with
adverse prognosis and reduced survival (P = .0006) [86].
Of these four SSX family members, SSX2 was found to be
the most strongly associated with worse prognosis (P =
.0001). Other MM patients not expressing all four of these
SSX family members were often found to express one or
more SSX proteins. In addition to MM, SSX2 expression
in prostate cancer has been reported by our group to be
associated with advanced-stage prostate cancer [74].
Like normal testis cells, the overall expression of SSX
p r o t e i ni nh u m a nt u m o rt i s s u es a m p l e sh a sb e e ns h o w n
to be quite heterogeneous in expression [68]. SSX nuclear
staining was found in one report to be present in 24%
of melanoma locoregional metastases and 40% of primary
melanoma tissue. Within the majority of all lesions less
than 25% of the tumor cells were found to be SSX positive.
Staining was observed in four main patterns, (a) widespread,
with >75% of cells expressing, (b) focal, with clustered
positive cells in a limited tumor area, (c) scattered, with
a few positive cells localized throughout the lesion, or (d)
isolated, with just a few positive cells in several tumor areas.
This heterogeneous expression has been a major concern
for tumor immunotherapy since the outgrowth of antigen-
negative cells might develop with targeted antigen-speciﬁc
therapy.
Since SSX expression has been shown in mesenchymal
stem cells [66], melanoma stem cells [94], and only hetero-
geneously in many tumor types, it may be necessary to use
agents to increase SSX antigen expression in tumor tissue
to therapeutically target these antigens. Within tumor tissue
it may be that cells expressing SSX proteins are stem cells,
dividing cells, or those that have malignant potential, and
perhaps this is why SSX expression appears so heterogeneous
in tumor lesions. These may be precisely the cells of most
interest for therapeutic targeting. Conversely, if not all
malignant cells express the SSX antigen, then outgrowth
of SSX-negative escape variants could potentially develop.Clinical and Developmental Immunology 9
Table 1: SSX family members: expression, fusion constructs, inducibility, and isoforms. The mRNA expression patterns of the ten known
SSX family members are shown for testis and tumor tissues in columns 2, 3, and 4, while SSX family members known to be involved in the
SS18-SSX fusion event are shown in column 5. SSX members shown to be inducible with epigenetic modifying agents or known to have
alternative splice isoforms are shown in columns 6 and 7, respectively. References are given in column 8.
Transcribed Expressed in testis Expressed in cancer Fusion partner with SS18 Inducible Alternative splices Reference
SSX1 + + + + + [27]
SSX2 + + + + + + [27, 74]
SSX3 + + −∗ − [27]
SSX4 + + + +∗∗ ++ [ 27]
SSX5 + + +/− ++ [ 27]
SSX6 + −− ∗ +/− [29]
SSX7 + + −∗ − +[ 29]
SSX8 + + −− [29, 73]
SSX9 + + −− [29, 73]
SSX10 + n.d n.d n.d. n.d. n.d. —
+ = positive/strong, +/− = positive/weak, − = negative/undetectable.
∗very seldom.
∗∗Only one case observed [75].
n.d. = not demonstrated.
Recent work with epigenetic modifying agents may present
one possible solution to this problem. In a report by dos
Santos et al. it was found that SSX2 mRNA and protein
expression could be induced with 5-aza-2 -deoxycytidine (5-
aza-dc) treatment in cultured BLM melanoma cells (SSX-
negative) and K562 erythroleukemia cells (SSX-positive)
[68]. Speciﬁcally, RT-PCR showed that SSX mRNA expres-
sion was clearly induced in BLM cells and increased in K562
cells with 5-aza-dc treatment, while SSX protein expression
was found by immunoﬂuorescence staining in 9–13% of all
treated cells. No protein expression was found in the absence
of 5-aza-dc treatment. SSX expression has also been shown
to be upregulated with 5-aza-dc in bladder cancer cell lines
that are SSX-negative prior to treatment [95], and SSX2 has
been shown to be inducible with 5-aza-dc in mesothelioma
[85]. We have also reported that SSX2 expression can be
upregulated selectively in prostate cancer cell lines, but not
normal prostate epithelial cells, by treatment with 5-aza-dc
[74]. In a report by G¨ ure et al. it was found that SSX4 was
inducible with the histone deacetylase inhibitor Trichostatin
A (TSA) in melanoma cell lines, with minor eﬀects for SSX2
and SSX6, whereas 5-aza-dc was able to more eﬀectively
induce expression of SSX1, 2, 4, and 5 in melanoma cell lines
[29]. SSX6 expression was only slightly inducible with 5 aza-
dcinthesestudies,andoverall,SSX4wasthemostfrequently
induced family member in these particular cells, followed by
SSX2, SSX5, SSX1, and SSX6 (Table 1). Finally, in another
report by Sigalotti et al. it was shown that upregulation of
SSX expression in melanoma cell clones with 5-aza-dc treat-
ment was directly correlated with promoter demethylation
patterns. This ﬁnding provided a clear mechanism of action
for upregulating CTA expression in cancer cells with DNA
methyltransferase inhibitors, which was thought to explain
the intratumoral heterogeneity of CTA expression patterns,
and provided further support for the use of pharmacologic
agents to upregulate antigen expression on tumor cells for
targeted tumor immunotherapy [96].
6.SSXImmunology
The interest in SSX proteins as immunotherapeutic targets
began with the identiﬁcation of SSX2 as the tumor antigen
HOM-Mel-40 [22], which had been shown to be the target
of humoral immune responses in as many as 10% of patients
with melanoma [22, 97, 98]. In other studies humoral SSX2
immune responses were observed in 2 out of 74 colon cancer
patient sera samples [99], 1 out of 100 prostate cancer
patient sera [74], and antibody responses to SSX4, but not
SSX2, have been identiﬁed in 2 out of 131 patients with
gynecological cancers but not in healthy controls [100]. SSX
common antigen antibody responses have also been detected
in sera from pancreatic, lung, breast, colon, and ovarian
cancer patients but not in healthy control individuals [101].
Additionally, antibodies speciﬁc for SSX1, 2, 3, and 4 have
been found in the sera of cancer patients with melanoma,
colon cancer, and/or breast cancer [27, 99, 102]. In another
study by Valmori et al. analysis of SSX4 IgG immune
responsesinepithelialovariancancer(EOC)patientsshowed
that two patients out of 109 had both SSX2 and SSX4 IgG
antibody responses [103]. These responses were conﬁrmed
by ELISA, and both patients with dual antibody responses
were alive and showed antibody responses >5y e a r sa f t e r
initial therapy.
Observing that cancer patients can have preexisting SSX2
IgG-speciﬁc immune responses, other investigators sought
to identify if cancer patients can have cell-mediated immune
responses to SSX proteins. Ayyoub et al. carried out the ﬁrst
investigation to identify SSX2 T-cell epitopes by utilizing
an altered reverse immunology strategy [104]. Puriﬁed10 Clinical and Developmental Immunology
Table 2: Expression of SSX family members in cancers of diﬀerent histological types. The expression of SSX family members 1–10 are shown
for 24 cancers of varying histological origin and in normal testis tissue. “+” indicates that the presence of SSX mRNA or protein has been
detected in these tumor tissues.
SSX1 SSX2 SSX3 SSX4 SSX5 SSX6 SSX7 SSX8 SSX9 SSX10 References
Bladder cancer + + + [76]
Breast cancer + + + [22, 76–78]
Cholangiocarcinoma + [79]
Colorectal carcinoma + + + + [22, 76, 80]
Endometrial cancer + + + + [76]
Gastric carcinoma + + [22, 76, 78]
Glioma + + [22, 76]
Head and neck cancer + + + + [76]
Hepatocellular carcinoma + + + + [22, 81]
Hodgkin’s lymphoma + + + [82]
Leiomyosarcoma [76]
Lymphoma/Leukemia + + + [22, 76, 83]
Lung cancer + + + + [22, 76, 84, 85]
M e l a n o m a ++ ++ + ∗ +∗ [22, 29, 76]
Multiple myeloma + + [86]
Neuroblastoma + + [87]
Non-Hodgkin’s lymphoma + + + [88]
O s t e o s a r c o m a ++ ++ [ 89]
Ovarian cancer + [22, 76]
Pancreatic cancer + [90, 91]
Prostate cancer + [22, 74, 76]
Renal cell carcinoma + [22, 76]
Synovial sarcoma + + + [76]
Thyroid cancer + [22, 76]
N o r m a l t e s t i s t i s s u e +++++ +++ [ 29, 73]
∗Only observed in cell lines.
standard proteasome complexes from human erythrocytes
were incubated in vitro with a library of overlapping SSX2
peptides covering the entire 188 aa protein sequence. The
digested products were analyzed by mass spectrometry,
which identiﬁed 12 peptides that were processed from the
proteasome: SSX2p5–13, p7–15, p15–24, p16–24, p40–49,
p41–49, p50–59, p53–61, p57–65, p58–67, p59–67, and
p103–111. These peptides were subsequently cultured with
cells from the tumor-inﬁltrating lymph node (TILN) of an
SSX2-positive metastatic melanoma lesion (LAU 50), and
an IFNγ-ELISPOT was performed to detect SSX2 peptide-
speciﬁc T-cell immune responses. SSX2 peptide p41–49
elicited the greatest T-cell immune response from the TILN,
which led the group to synthesize HLA-A2 multimers
containing SSX2 peptide p41–49 (Table 3). These multimers
were used to stain the TILN cells and showed clearly positive
SSX2 p41–49-speciﬁc CD8+ T cells. It was also shown that
SSX2p41–49 CD8+ T cells (CTL clone LAU 50 E2.4) could
lyse peptide-pulsed T2 cells and HLA-A2+ melanoma cell
lines.Interestingly,whenthisclonewasincubatedwithCOS7
cells transfected with plasmids encoding HLA-A2 and SSX2
orSSX4,highlevelsofIFNγ secretionandlysiswereobserved
by the clone with SSX2-transfected cells but not SSX4-
transfected cells. Since SSX2 and SSX4 only diﬀer by 2 aa
withintheantigenicepitoperegion,thisresultsuggestedhigh
speciﬁcity of the clone for SSX2 p41–49. None of the other
predicted SSX2 epitopes were recognized by TILN from this
patient.
Following on this work, Ayyoub et al. utilized ﬂuorescent
HLA-A2/SSX2p41–49 multimers to determine the relative
frequencies of SSX2 p41–49 CD8+ T cells in melanoma
patients with SSX2-positive or negative tumors and in
healthy donors [105]. They found that SSX2 p41–49-speciﬁc
CTLs were identiﬁable in both melanoma patients andClinical and Developmental Immunology 11
Table 3: SSX epitopes: sequences, haplotype restrictions, and recognition. The known SSX immunogenic class I and class II MHC peptides
or epitopes are shown. Amino acid sequence, haplotype restriction, tumor presentation, family member recognition, and references are
outlined for each peptide/epitope. Symbol designations include + = SSX4 sequence, n.d. = not demonstrated. † = p41–49 epitope shown to
be recognized on Me 275, SK-MEL-37, T343B, and T567A melanoma cells and SW 872 liposarcoma cells; p103–111 shown to be recognized
on SK-MEL-37 melanoma cells and LNCaP prostate cancer cells; and p45–59 shown to be recognized on Me 275 cells. ∗ = Recognized on
antigen-loaded dendritic cells but not endogenously presented by tumor cells.
Class Name Native peptide sequence Haplotype
Naturally
presented by
SSX+ tumor
cells
Known family
member
recognition
Reference
I
p41–49 KASEKIFYV HLA-A∗0201 Y† SSX2 [104–106]
p57–65 AMTKLGFKA HLA-A∗0201 n.d. SSX1–9 [107]
p103–111 RLQGISPKI HLA-A∗0201 Y† SSX2 [108, 109]
II
p19–34 EKIQKAFDDIAKYFS HLA-DPB1∗0101 n.d.∗ SSX2 [110]
p37–51 WEKMKASEKIFYVYM HLA-DR3∗0301 n.d.∗ SSX2, SSX4,
SSX5
[111]
p45–59 KIFYVYMKRKYEAMT
HLA-DRB1∗1101,
∗0701, ∗1101,
∗1302, and B3∗0301
Y† SSX2 [112, 113]
p21–40 RSKAFDDIATYFSKKEWKKM HLA-DRB1∗1501 n.d.∗ SSX1 [114]
p31–50 YFSKKEWEKMKSSEKIVYVY+ HLA-DRB∗0301
and ∗1101 (SSX4) n.d.∗ SSX1, SSX4 [114, 115]
p41–60 KSSEKIVYVYMKLNYEVMTK+
HLA-DRB1∗1501 or
DRB5∗0101 (SSX4)
and HLA-DR1∗1601
(SSX1)
n.d.∗ SSX1, SSX4 [114, 115]
p51–70 MKLNYEVMTKLGFKVTLPPFM+ HLA-DRB1∗0701
(SSX4) n.d.∗ SSX1, SSX4 [103, 114, 115]
p61–80 LGFKVTLPPFMRSKRAADFH HLA-DRB1∗1101 n.d.∗ SSX4 [115]
p101–120 FGSLQRIFPKIMPKKPAEEE+ HLA-DRB1∗1101
(SSX4) n.d.∗ SSX1, SSX4 [114, 115]
p141–160 PPGKANISEKINKRSGPKRG HLA-DR1∗1601 n.d.∗ SSX1 [114]
p151–170 INKTSGPKRGKHAWTHRLRE HLA-DPB1∗1001 n.d.∗ SSX4 [115]
p161–180 KHAWTHRLRERKQLVVYEEI HLA-DRB1∗08 and
HLA-DRB3∗0202 n.d. SSX4 [103]
healthy donors, although at lower frequency in healthy
donors or patients with SSX2-negative tumors. They showed
that p41–49-speciﬁc CTLs from the TILN and peripheral
blood mononuclear cells (PBMCs) of patients with SSX2-
expressing tumors were better able to lyse tumor cells com-
paredtoCTLsfromtheTILNandPBMCsfrompatientswith
SSX2-negative tumors or PBMCs from healthy donors. It
was also shown that SSX2-speciﬁc CTL frequency increased
with disease progression in at least one melanoma patient.
SSX2 p41–49 T cells have also been identiﬁed in patients
with hepatocellular carcinoma (HCC) [116]. These CD8+ T
cells were identiﬁed using SSX2 p41–49/HLA-A2 multimers
in one out of six patients with HCC, both in the TILN
and PBMCs. A polyclonal SSX2 p41–49 T-cell line generated
from this patient lysed p41–49-pulsed T2 cells, melanoma
cell line MEL 275, and a p41–49 peptide-pulsed HCC cell
line. This was the second solid human malignancy with
evidence of recognition by SSX2 p41–49-speciﬁc CTL.
The immunogenicity of SSX2 p41–49 was later high-
lighted when Rubio-Godoy and colleagues identiﬁed this
peptide through an approach called positional scanning of
synthetic combinatorial peptide library analysis [117]. In
this report, 3.1 × 1011 nonamer peptides, arranged in a
positional scanning format, were screened for melanoma-
reactive CTL of unknown speciﬁcity and assessed for their
ability to elicit peptide-speciﬁc CTL. The identiﬁed optimal
peptide sequence (AAAPKIFYA) was very similar to SSX2
peptide p41–49 (KASEKIFYV). Recognition of this epitope
by melanoma-reactive CTL clone LAU 50/4D7 was con-
ﬁrmed by cytotoxicity assay, and interestingly, the native
SSX2 peptide p41–49 had recognition that was in the same
range as the optimal peptide. Attempts to modify the anchor
residuesoftheoptimallyidentiﬁedpeptideorthenativep41–
49 epitope did not result in enhanced peptide recognition.
Additionally, no cross-reactivity of p41 from SSX1, SSX3,
SSX4, or SSX5 was observed. Further, a biometrical analysis
of the screening data was used to generate a scoring matrix
of all predicted peptides in public protein databases that
could potentially be recognized by clone LAU 50/4D7, and,
amazingly, this approach ranked SSX2 p41–49 27th out of
approximately 16 million nonamer peptides [118]. If this
analysis was restricted to known tumor antigens in humans,12 Clinical and Developmental Immunology
this rank was 2nd out of 400,271 peptides. Ranked scores
for other SSX peptides were much lower, however. It was
noted that this method of scoring does not omit other SSX
peptides as potentially immunogenic, but it does emphasize
the immunogenicity of SSX2 p41–49.
In an eﬀort to identify additional class I MHC-restricted
SSX2 epitopes, Wagner et al. used a reverse immunology
approach to identify SSX2 epitopes that were predicted to
have aﬃnity for the human HLA-A2 MHC class I complex
using the SYFPEITHI algorithm [108, 119]. PBMCs from
seven breast cancer patients and eleven healthy donors
were evaluated for reactivity to peptides p41–49 and p103–
111, and p167–175, which had all been predicted from
the peptide-binding algorithm to have aﬃnity for HLA-
A2. They found that 5/7 (71%) of the HLA-A2+ breast
cancer patients and 6/11 (55%) of the HLAA2+ healthy
controls had T cells that were reactive to SSX2 peptide
p103–111 by IFNγ-ELISPOT assay. HLA-A2 restriction of
the responses was veriﬁed using speciﬁc HLA blocking
antibodies. SSX2 p103–111 was also shown to be a naturally
presented SSX2 epitope by the recognition of SSX2+ SK-
MEL-37 melanoma cell line and transfected COS7 cells by
p103–11 peptide-speciﬁc CD8+ T cells (Table 3). Also, SSX2
p103–111-speciﬁc T cells could lyse peptide-pulsed target
cells in cytotoxicity assays. Interestingly, no association was
found between SSX2 antibody titer in breast cancer patient
serum and p103–111-speciﬁc T-cell responses, indicating
that the humoral and cell-mediated responses to this antigen
are regulated independently. Rentzsch and colleagues found
that PBMCs from one out of ten primary breast cancer
patients exposed to SSX2-p103–111 signiﬁcantly increased
their mRNA expression of IFNγ by QT-RTPCR analysis
[109]. This immune response was also detected in one of
eleven healthy control individuals. We have also recently
identiﬁed SSX2 p103–111 as an SSX2 epitope using HLA-A2
transgenic mice immunized with a genetic vaccine encoding
SSX2, and further identiﬁed that p103–111-speciﬁc CTL
can lyse HLA-A2-expressing prostate tumor cells (Smith,
manuscript submitted).
Not only has the endogenous processing and presen-
tation of SSX2 peptide p103–111 been demonstrated by
reactivity of p103–111-speciﬁc CTL for SSX2-expressing
tumor cells, it has also recently been shown that this peptide
epitope is directly presented on the surface of cancer cells
[73]. By utilizing a human phage library screening technique
Held et al. generated SSX2 p103–111-speciﬁc Fab antibodies
that speciﬁcally recognized and bound to this peptide in
the context of HLA-A2. These antibodies were used to stain
melanoma cell lines in ﬂuorescence microscopy studies, and
it was observed that a majority of SK-Mel-37 cells expressed
p103–111/HLA-A2, whereas Me275 cells expressed very little
(<1% of cells). These cells were also used to stimulate SSX1
p103–111-speciﬁc T cell clones, and it was determined that
the expression of p103–111/HLA-A2 on the cell surface, and
not the total SSX2 protein expression levels of the cells, was
correlated with enhanced CTL recognition and activation.
Ayyoub et al. also identiﬁed the ﬁrst CD4 class II MHC
SSX2 epitope [110]. This epitope was mapped to aa 19–34
of SSX2 using truncated peptide assays and was recognized
by CD4+ T cells from an SSX2-expressing melanoma patient
(Table 3). No responses to this epitope were found in healthy
controls, and class II blocking antibody experiments veriﬁed
that this epitope is recognized in the context of HLA-
DPB1∗0101. Many studies have documented the atypical
expression of class II MHC molecules on the surface of colon
carcinomas, breast cancer cells, sarcomas, and melanoma
cells [120–124]. This expression prompted the investigators
in the current study to evaluate whether SSX2 p19–34 is
processed endogenously and presented on the surface of
tumor cells. Interestingly, SSX2 CD4+ T cells failed to
recognize IFNγ-treated melanoma cells expressing SSX2 and
class II MHC molecules (HLA-DP); however, they were
stimulated by antigen-loaded dendritic cells. This result
suggests that p19–34 may not be endogenously presented on
tumor cells but can be loaded exogenously and presented
by APCs. Ayyoub et al. also identiﬁed an HLA-DRB∗1101-
restricted SSX2 class II peptide p45–59 [112]. CD4+ T cells
speciﬁc for this epitope were detected among PBMCs and
in the TILN from melanoma patients but not in healthy
control individuals. Using the SYFPEITHI algorithm, p45–
59wasrankedasthe2ndhighestpredictedHLA-DR-binding
peptide for SSX2, whereas this peptide ranked 3rd, 13th,
and 2nd for SSX1, SSX4, and SSX5, respectively. Titrated
concentrations of peptides incubated with p45–59-speciﬁc
CD4+ T cells showed cross-reactivity to SSX5 p45–59 and
low-level reactivity to SSX1 p45–59 in IFNγ ELISA assays.
Eleven of nineteen melanoma patients had CD4+ T cells
responses to this epitope region (i.e., aa 37–58). Contrary
to what was found for the class II peptide p19–34, T cells
recognized epitope p45–59 on both antigen-loaded DCs
as well as HLA-DR+ tumor cells. This peptide was also
described by Neumann and colleagues in which p45–59 was
f o u n dt ob er e s t r i c t e dt oH L A - D R B 1s u b t yp e s∗0701, ∗1101,
∗1302 and B3∗0301, and it was demonstrated that p45–59
CD4+ T cell responses could be induced in 3/6 of breast
cancer patients and 1/5 of healthy controls [113]. However,
no correlation was found between SSX2 antibody titer and
CD4+ T cell responses.
After the identiﬁcation of the ﬁrst two class II SSX2
epitopes Ayyoub and colleagues identiﬁed yet another CD4
peptide that overlapped with these epitopes [111]. This
epitope region was narrowed down to amino acids p37–
51 of SSX2 by truncation experiments and was shown to
be restricted to HLA-DRB∗0301 by class II MHC blocking
antibody assays. Since this was the third immunogenic
peptide identiﬁed in the KRAB domain region of SSX2, it
was theorized that this region may be a “hot spot” for T-cell
recognition. Again, wild type melanoma cell lines expressing
MHC class II molecules or tumor cells transfected with
plasmid encoding SSX2 were not recognized by epitope-
speciﬁc CD4+ T cells directly, however, p37–51 peptide-
pulsed tumor cells were recognized by both SSX2 p37–51-
speciﬁc CD4+ T cells and SSX2 p41–49 peptide-speciﬁc
CD8+ T cells. Of note, the transfected cells were recognized
by the p41–49-speciﬁc T cells but not the p37–51-speciﬁc
CD4+ T cells, conﬁrming that the p41–49 peptide can be
endogenously processed and presented by tumor cells. Cross
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for SSX4 and SSX5 but not SSX1 or SSX3 p37–51 peptides in
an IFNγ peptide titration ELISA assay.
Since it was previously observed that SSX4 was expressed
in ∼20% of malignant melanomas in a report by T¨ ureci et al.
[76], Ayyoub and colleagues also evaluated the presence of
CD4+ T cells speciﬁc to this antigen in melanoma patients
by stimulating CD4+ T cells isolated from the PBMCs of
four melanoma patients with overlapping peptides derived
from the amino acid sequence of SSX4 in the presence of
APCs [115]. Intracellular IFNγ cytokine staining revealed
that all four patients had CD4+ T cells that were activated in
the presence of at least one of the SSX4 peptides (Table 3).
Again, as was found for the SSX2 class II peptides, CD4+
T cells could not recognize melanoma cells directly but
were activated by APCs loaded with SSX4 antigen, which
suggested that this peptide may not be presented through
the endogenous pathway in tumor cells. Interestingly, ﬁve
out of the seven peptides identiﬁed in this study mapped to
the KRAB domain of SSX4. Four previously identiﬁed SSX2
epitopes also mapped to this region, further suggesting that
this may be a “hot spot” for T-cell recognition. Valmori et al.
found that epithelial ovarian cancer (EOC) patients also had
SSX4 CD4+ T cells that recognized some of these epitopes
[103].
Several of the SSX4 class II peptides that were identiﬁed
previously were later reported by Godefroy et al. to also
be epitopes encoded from the SSX1 protein [114]. In this
study an overlapping pool of peptides spanning the entire
SSX1 protein sequence was incubated with PBMCs from
cancer-free individuals; SSX1-peptide-speciﬁc CD4+ T cells
were identiﬁed in 5/5 of the donors analyzed. These T-
cell populations almost exclusively recognized epitopes from
three deﬁned regions of the protein sequence, including
the KRAB domain and two C-terminal regions of the
protein that are retained in the SS18-SSX fusion construct
(Table 3)[ 115]. Evaluating the cross-reactivity of these
peptide-speciﬁc clones for other SSX family members,
however, revealed only limited recognition of p41–60 for
SSX5. This lack of cross-reactivity was explained by the
presence of several amino acid diﬀerences in this epitope
region between family members. As before, no endogenous
processing and presentation of SSX1 epitopes by tumor cells
was demonstrated.
Since it had been shown that tumors can express more
than one SSX family member at the same time and that T-
cell responses can be found to multiple SSX family members
in cancer patients, He et al. assessed the utility of an altered
peptide ligand strategy to identify class I epitopes that could
be used to target multiple SSX family members [107]. Using
peptide prediction algorithms He and colleagues identiﬁed
SSX p57–65 and p99–107 as shared epitopes between family
members SSX1–9. Since SSX p57–65 had the higher binding
score for all nine family members, this peptide was selected
forfurtheranalysis.UsingT2bindingassayswithfouraltered
p57–65peptidesspeciﬁctoSSX1–9,itwasshownthataltered
peptide P4 (AMTKLGFNV), which is encoded by SSX6 and
SSX8, had the greatest in vitro binding aﬃnity for HLA-A2,
and this aﬃnity was stable at low peptide concentrations.
All four altered p57–65 peptides were shown to elicit
peptide-speciﬁc CTL from the PBMCs of healthy HLA-
A∗0201 individuals, however P4-speciﬁc CTL showed the
greatest lysis and IFNγ secretion when incubated with
peptide-pulsed target cells. Additionally, P4 showed the
greatest cross-reactivity to other altered p57–65 peptides
presented by target cells in cytotoxicity assays. HLA-A2.1/Kb
mice immunized with P4 generated CTL that could be
cultured ex vivo, and were shown to also lyse T2 cells
displaying the immunizing peptide or the three other altered
p57–65 peptides, which suggests that this altered peptide
strategy might be successfully utilized to target multiple SSX
family members (Table 3).
7. Concluding Remarks andFutureDirections
The SSX proteins are a highly homologous group of CT-
X antigens with demonstrated immunogenicity in patients
with cancer, and a number of characteristics that make them
attractive targets for tumor therapy. Cheever et al. recently
reportedthatSSX2inparticularmaybeahighpriority target
for cancer therapy based upon certain predeﬁned criteria for
prioritization of tumor antigens, such as tumor speciﬁcity,
oncogenicity, expression level, and number of identiﬁed
epitopes [14]. As essentially tumor-speciﬁc antigens from
the immunological perspective, SSX proteins may therefore
represent ideal targets for tumor immunotherapy.
As described previously, several groups have demon-
strated that SSX mRNA or protein expression in tumors is
correlated with more advanced stages of disease and a worse
patient prognosis. More work needs to be done to evaluate
the function of SSX proteins in cancer to determine if the
expression of these proteins is a bystander eﬀectof epigenetic
reprogramming or whether the proteins themselves have
inherent transforming activity and contribute to the cancer
phenotype.Forinstance,ithasbeenshownthatSSXproteins
in mesenchymal stem cells colocalize with MMP2, and
in knock-down studies it appears that SSX expression is
correlated with an invasive phenotype [66]. Additionally,
the presence of SSX in the SS18-SSX fusion construct
that is expressed in >95% of SS appears to contribute to
transformation as well [15], and may be a reasonable target
for drug or vaccine-based therapy. Although this fusion
protein is expected to have a diﬀerent function than native
SSX proteins, the frequent association of SSX proteins with a
cancer phenotype suggests a possible functional role leading
to tumor formation.
Due to their high degree of homology and the iden-
tiﬁcation of conserved “hot spots” of epitope recognition,
it might be feasible to target multiple SSX family member
proteins simultaneously in tumors coexpressing these SSX
family members. For instance, it may be possible to elicit
immune responses to these proteins by immunizing patients
with vaccines encoding native SSX peptides or protein, or
modiﬁed vaccines designed to target several SSX family
members. Moreover, the ability to modulate SSX protein
expression with epigenetic modifying agents might provide
a means to increase SSX expression in tumor tissue for
targeted immunotherapeutic approaches. However, until it14 Clinical and Developmental Immunology
has been established whether SSX proteins contribute to
oncogenicity, it may not be prudent to use epigenetic means
toincreasetheexpressionoftheseproteinsinhumanpatients
for clinical immunotherapy trials before it can be shown
that this expression would not be harmful. In regard to
concerns of transforming activity by the SSX proteins, the
ideal immunization platform for therapeutic vaccines may
be either SSX peptides or a genetic vaccine encoding a
rearranged version of SSX cDNA. This could potentially
allow for the transcription and translation of key SSX
epitopesthatcanbepresentedtoTcellswithoutthepotential
harmful eﬀects that might develop from direct vaccination
with SSX proteins or with gene-based vaccines encoding the
native protein.
The identiﬁcation of several orthologues of SSX proteins
in a variety of mammalian species may provide additional
model systems to evaluate the eﬃcacy of targeting these
antigens therapeutically. Since these orthologues appear to
have similar expression patterns in testis and tumor tissue,
it is likely that SSX proteins have conserved evolutionary
function, and further investigation of these proteins in
other species may shed light on their mechanistic roles
in both normal and malignant tissues. Based upon the
available information gathered for these proteins, either
drug-based therapies or vaccine-based immunotherapies
could potentially be developed to treat patients with tumors
expressing these antigens.
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